indication

Schizophrenia, Paranoid

Competitive landscape

as of 2026-07-01
Competitive set
5
5 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
41 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 32 trials
OwnerOrganon and Co
Protection2033
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
—1 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 41 trial
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugUnknown
Risperidone
US-approved 1993 · RISPERDAL
—1 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042

Market size

prevalence as a range, not a number